Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: S&P Capital IQ Quantitative Report
$104.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

MediciNova, Inc announces positive interim results of Phase 2a Study of MN-166 in Opioid Dependence


Monday, 18 Aug 2014 07:00pm EDT 

MediciNova, Inc:Announces positive interim results of a Phase 2a clinical trial of MN-166 (ibudilast) in opioid dependence.The study is being conducted at Columbia University and the New York State Psychiatric Institute and led by Sandra Comer, Professor of Neurobiology.The interim analysis was performed after the first seven patients had completed the study, which required a 6-week stay on the inpatient unit.Says this data is complementary to the data from the company's previous study in heroin abusers, in which ibudilast demonstrated a reduction in withdrawal symptoms.Says the data also confirms the positive effects of ibudilast on analgesia which the company have seen in a previous study. 

Company Quote

323.0
-45.0 -12.23%
17 Sep 2014